Bio-Techne’s Asuragen Launches High-Sensitivity ESR1 Mutation Monitoring Assay for HR+ Metastatic Breast Cancer Research
Bio-Techne Corporation, through its Asuragen brand, has launched a groundbreaking ESR1 mutation monitoring assay aimed at advancing research in hormone receptor-positive (HR+) metastatic breast cancer. This research-use-only assay, featuring a QuantideX qPCR ESR1 exoMutation Kit and an ExoLution Plus cfDNA + exoRNA Isolation Kit, was showcased at the San Antonio Breast Cancer Symposium.
Tackling Resistance in HR+ Metastatic Breast Cancer
ESR1 gene mutations, though rare prior to treatment, emerge in up to 40% of HR+ metastatic breast cancer patients undergoing endocrine therapy. These mutations signify the onset of treatment resistance, necessitating rapid detection for timely intervention. However, traditional molecular testing technologies often lack the sensitivity required for reliable detection at early stages.
Asuragen’s new assay addresses this gap with exceptional sensitivity, enabling the detection of 11 ESR1 ligand-binding domain mutations in samples. By integrating data from cell-free DNA (cfDNA) and exosomal RNA (exoRNA), the assay offers unprecedented accuracy, previously achievable only through costlier and more cumbersome methods.
User-Friendly and Cost-Effective Solution
Designed to work seamlessly with widely available qPCR technology, Asuragen’s ESR1 mutation assay eliminates the need for expensive platform upgrades. This ensures cost-effective implementation and broad accessibility in research settings.
Dr. Matt McManus, President of Bio-Techne’s Diagnostics and Spatial Biology Segment, emphasized:
“With a growing number of candidate drugs targeting ESR1 mutations in clinical trials, laboratory scientists need highly sensitive tools to detect these mutations early in patients treated with endocrine therapies. Our expertise in qPCR-based assays and exosome data extraction uniquely positions Bio-Techne to provide a streamlined and robust ESR1 mutation assay for research use.”
Advancing Breast Cancer Research
The ESR1 mutation monitoring assay empowers researchers to:
- Detect early molecular signals of treatment resistance.
- Monitor the effectiveness of endocrine therapies.
- Facilitate advancements in drug development targeting ESR1 mutations.
Though intended strictly for research purposes and not for diagnostic use, this innovation represents a significant step forward in addressing the challenges of metastatic breast cancer.
About Bio-Techne Corporation
Bio-Techne Corporation is a global leader in life sciences, offering innovative tools and reagents for research and clinical diagnostics. The company’s products support scientific advancements in understanding biological processes and disease progression.
For more information, visit Pharmacy InfoLine.
About Author
